title: Plasma catestatin level in patients with acute myocardial infarction and its correlation with ventricular remodelling.
abstract: BACKGROUND
  The evaluation of ventricular remodelling and functional recovery is essential in predicting the prognosis of patients with acute myocardial infarction (AMI).
  
  
  OBJECTIVE
  To determine the plasma catestatin level in patients with AMI, and investigate the association between plasma catestatin and heart function, and with left ventricular remodelling (LVR).
  
  
  METHODS
  Fifty-eight consecutive patients who were admitted within 12 h of the onset of their ST-segment elevation myocardial infarction symptoms between 1 October 2009 and 30 June 2011 were prospectively recruited. Circulating catestatin was measured by ELISA. All patients underwent an echocardiography examination during the first week; 31 patients had a second echocardiography examination 3 months after the myocardial infarction.
  
  
  RESULTS
  Plasma catestatin at the time of admission was significantly higher in patients than in normal controls. The level increased further in the first week after AMI. Three months after AMI, the plasma catestatin level of patients was comparable to that of normal controls. The plasma level of catestatin correlated with anterior AMI and left ventricular ejection fraction (LVEF) in the acute stage. Compared with patients without LVR, those with LVR had significantly higher level of plasma brain natriuretic peptide on day 7 and a significantly higher level of plasma catestatin on admission and on days 3 and 7 (p=0.033, p=0.001, p=0.006, p=0.021, respectively).
  
  
  CONCLUSIONS
  Plasma catestatin levels were raised after AMI. An early increase of catestatin correlated with anterior AMI and LVEF. Plasma catestatin after the onset of AMI might be associated with the magnitude of progressive ventricular remodelling 3 months after AMI.
authors.affiliation: Department of Cardiology, Peking University First Hospital, Beijing 100034, PR China. menglei@medmail.com.cn
authors.forename: Lei
authors.initials: L
authors.lastname: Meng
authors.forename: Jie
authors.initials: J
authors.lastname: Wang
authors.forename: Wen-hui
authors.initials: WH
authors.lastname: Ding
authors.forename: Ping
authors.initials: P
authors.lastname: Han
authors.forename: Ying
authors.initials: Y
authors.lastname: Yang
authors.forename: Li-tong
authors.initials: LT
authors.lastname: Qi
authors.forename: Bao-wei
authors.initials: BW
authors.lastname: Zhang
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood; D002681:China / Q000453:epidemiology; D053379:Chromogranin A / Q000097:blood*; D004452:Echocardiography; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000401:mortality / Q000503:physiopathology; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D010446:Peptide Fragments / Q000097:blood*; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D013318:Stroke Volume; D013997:Time Factors; D018487:Ventricular Dysfunction, Left / Q000097:blood* / Q000401:mortality / Q000503:physiopathology; D020257:Ventricular Remodeling
chemical_list: D015415:Biomarkers; D053379:Chromogranin A; D010446:Peptide Fragments; C109084:chromogranin A (344-364); D020097:Natriuretic Peptide, Brain